|
High exosomal PD-L1 expression in relation to lymph node progression in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (abi) or enzalutamide (enza). |
|
|
Consulting or Advisory Role - Amgen; Astellas Amgen BioPharama; AstraZeneca/Merck; Janssen |
Speakers' Bureau - Bristol-Myers Squibb |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; Sanofi |
|
|
Consulting or Advisory Role - Celgene; Ipsen; Janssen-Cilag; Roche Molecular Diagnostics; Sanofi |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol Myers Squibb; Janssen; Janssen |
Travel, Accommodations, Expenses - Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Blue Earth Diagnostics; Foundation Medicine; Janssen Oncology; Loxo/Lilly; Pfizer |
Research Funding - Abbvie/Stemcentrx (Inst); Bristol Myers Squibb Foundation (Inst); Janssen (Inst) |
Travel, Accommodations, Expenses - Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |